详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Identification of a novel therapeutic target for lung cancer: Mitochondrial ribosome protein L9

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China [2]The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China [3]Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China [4]Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China [5]Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, University of Macau, Macao, China

出处：

DOI：

ISSN：

关键词： MRPL9 Lung cancer Bioinformatics c-MYC ZEB1

摘要：

Lung cancer has a high fatality rate and incidence rate. At present, the initial and progress mechanism of lung cancer has not been completely elucidated and new therapeutic targets still need to be developed. In this study, the screening process was based on lung cancer expression profile data and survival analysis. Mitochondrial ribosome protein L9 (MRPL9) was upregulated in lung cancer tissues and related to the poor overall survival rate and recurrence-free survival rate of lung cancer patients. Knockdown of MRPL9 inhibited the proliferation, sphere-formation, and migration ability of lung cancer cells. MRPL9 was associated with the c-MYC signaling pathway, and lung cancer patients with high expression of both MRPL9 and MYC had a poor prognosis. Furthermore, c-MYC was associated with the epithelial-mesenchymal transition (EMT) regulatory protein zinc finger E-box binding homeobox 1 (ZEB1) by bioinformatics analysis. The relationship between ZEB1 and c-MYC was further confirmed by interfering with c-MYC expression. MRPL9 is a potential therapeutic target for lung cancer and exerts its biological functions by affecting the transcription factor c-MYC thereby regulating the EMT regulator ZEB1.Copyright © 2023 Elsevier GmbH. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 4 区医学

小类 | 3 区病理学

最新[2025]版：

大类 | 4 区医学

小类 | 3 区病理学

第一作者：

第一作者机构： [1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

通讯作者：

通讯机构： [1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China [3]Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China [4]Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China [5]Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, University of Macau, Macao, China [*1]Department of Pathology, School of Basic Medical Sciences, Southern Medical University, No.1023 Shatai Road, Baiyun District, Guangzhou 510515 Guangdong, China. [*2]5005a, N22, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macao Special administrative regions of China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]VPS33B modulates c-Myc/p53/miR-192-3p to target CCNB1 suppressing the growth of non-small cell lung cancer. [2]Association Between c-Myc and Colorectal Cancer Prognosis: A Meta-Analysis [3]养正散结汤对裸鼠胃癌移植瘤生长及let-7a/c-Myc表达的影响 [4]氧化苦参碱对结肠癌LoVo细胞c-myc,PSMD9,CDK4mRNA表达的影响 [5]mRNA expression profile analysis reveals a C-MYC/miR-34a pathway involved in the apoptosis of diffuse large B-cell lymphoma cells induced by Yiqichutan treatment. [6]Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway [7]Artemisitene suppresses tumorigenesis by inducing DNA damage through deregulating c-Myc-topoisomerase pathway [8]MicroRNA-1294 inhibited oral squamous cell carcinoma growth by targeting c-Myc. [9]USP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis [10]PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus